









Markets
/
Stocks
/
nasdaq-algs
/

Aligos Therapeutics Inc

ALGS

7.320USD

+0.830+12.79%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

45.04MMarket Cap

LossP/E TTM



Aligos Therapeutics Inc

7.320

+0.830+12.79%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aligos Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Aligos Therapeutics Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 92 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 68.20.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aligos Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

92 / 392

Overall Ranking

219 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Aligos Therapeutics Inc Highlights

StrengthsRisks

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.94M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.94M.

Fairly Valued

The company’s latest PE is -0.54, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 55.02K shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

68.200

Target Price

+950.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Aligos Therapeutics Inc is 5.99, ranking 304 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 741.00K, representing a year-over-year decrease of 41.61%, while its net profit experienced a year-over-year decrease of 63.75%.

Score

Industry at a Glance

Previous score

5.99

Change



Financials

7.35

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.33

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.33

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Aligos Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Aligos Therapeutics Inc is 8.75, ranking 23 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.54, which is -45.26% below the recent high of -0.30 and -991.08% above the recent low of -5.89.

Score

Industry at a Glance

Previous score

8.75

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 92/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Aligos Therapeutics Inc is 8.40, ranking 124 out of 392 in the Biotechnology & Medical Research industry. The average price target is 55.00, with a high of 175.00 and a low of 36.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

68.200

Target Price

+950.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Aligos Therapeutics Inc

ALGS

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Aligos Therapeutics Inc is 6.48, ranking 235 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.68 and the support level at 5.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.13

Change

0.35

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.196

Sell

RSI(14)

40.767

Neutral

STOCH(KDJ)(9,3,3)

21.076

Neutral

ATR(14)

0.811

High Vlolatility

CCI(14)

-125.313

Sell

Williams %R

66.800

Sell

TRIX(12,20)

-0.978

Sell

StochRSI(14)

93.285

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

7.270

Buy

MA10

7.757

Sell

MA20

8.122

Sell

MA50

9.377

Sell

MA100

9.193

Sell

MA200

8.450

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Aligos Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 78.55%, representing a quarter-over-quarter decrease of 0.04%. The largest institutional shareholder is The Vanguard, holding a total of 200.40K shares, representing 3.74% of shares outstanding, with 41.33% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Woodline Partners LP

468.20K

-9.67%

Deep Track Capital LP

444.11K

Roche Holding AG

441.04K

-0.00%

Alyeska Investment Group, L.P.

412.00K

Sio Capital Management, LLC

335.94K

Readystate Asset Management LP

203.11K

+48.49%

The Vanguard Group, Inc.

Star Investors

171.69K

+22.83%

Adage Capital Management, L.P.

140.00K

Blatt (Lawrence M)

84.82K

-1.34%

Baker Bros. Advisors LP

83.06K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aligos Therapeutics Inc is 2.45, ranking 227 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.68. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Aligos Therapeutics Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.